SCHEMBL31172554

SCHEMBL31172554

COc1cc(C(=O)Oc2c(F)c(F)c(F)c(F)c2F)c(OC)cc1Cn1cccn1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 8/20 0.42
▸ KAT6A Q92794 8/20 0.42
▸ KAT6B Q8WYB5 6/20 0.42
▸ KMT2A Q03164 5/20 0.41
▸ MAPT P10636 4/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ NPSR1 Q6W5P4 3/20 0.41
▸ HTT P42858 3/20 0.40
▸ LMNA P02545 3/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KAT5 Q92993 2/20 0.39
▸ KAT8 Q9H7Z6 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172691 0.88 KAT7 (0.45) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172672 0.84 KAT7 (0.42) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172677 0.84 HTT (0.45) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172565 0.81 KAT7 (0.40) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172601 0.76 HTT (0.37) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172751 0.75 KAT7 (0.37) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172622 0.73 CNR1 (0.36) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172624 0.73 CNR1 (0.36) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL31172576 0.73 HTR2A (0.46) KAT7KAT6AKAT6BKMT2AMAPT
SCHEMBL553315 0.72 KLKB1 (0.47) KAT7KAT6AKAT6BKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 4/4885KAT6A 1/4885KAT6B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback